Global Health: What’s Ahead for 2022: Antimicrobial Resistance
Antimicrobial resistance (AMR), which is making a growing range of antibiotics ineffective, is anincreasingly critical problem. Driven la...
Global Health: What’s Ahead for 2022: Health Financing
It’s fair to say that the current state of health financing is mixed. On the one hand, outside of pandemic-related funding, public financ...
Global Health: What’s Ahead for 2022: Vaccines
Nothing in recent years has focused the world’s attention on the development, use, and efficacy of vaccines more than COVID-19. Through e...
ESG Reporting Regulations in the U.S. and EU: Looking Ahead
Comparing the road ahead for mandatory corporate ESG disclosures in the two markets.
Global Environmental Reporting Standards: What You Need to Know
Moving toward uniform environmental reporting standards to catalyze corporate performance.
G20 Health and Finance Ministers Meeting: A Crisis, An Opportunity, or Both?
Five things we will be looking for from G20 leaders, health and finance officials.
COP26: What You Need to Know
What business and organizations need to know about this critical moment for global engagement on climate resiliency.
Five Key Questions Raised by the U.S. Decision to Support a Temporary TRIPS Waiver for COVID-19 Vaccines
Key intellectual property issues to be addressed at the World Trade Organization, amid the ongoing COVID-19 response.
Climate Change: Top 5 Multilateral Engagement Opportunities
CMI insights on where business and civil society can engage global policymakers on climate change.
Ambassador Robert Holleyman on Data Governance and Trade
Analysis for The National Bureau of Asian Research on trade, data governance, and cross-border data flows in the Asia-Pacific.